michael wilhelm
scottsdale, AZ (USA)
Role(s):
C-Level Executive (CEO, CFO, etc.)
ImmuneRegen BioSciences
Find More Startups
Startup
Location:
scottsdale
Industry:
Bio-Technology
Year Founded:
2001
Number Employees:
1-10 people
Business Stage:
Growth (not profitable)
Entity Type:
"S" Corporation
Description:
IR BioSciences Holdings, Inc. (the “company” or “ImmuneRegen”) is engaged in the research and development of the potential drug candidate, Homspera® (also known as Sar9, Met (O2)11-Substance P) for use as an immunomodulatory agent and stimulator of human adult stem cells. The company is focused on developing therapeutics aimed at specific disease targets including influenza, cancers (solid and blood), pulmonary fibrosis and neutropenia. Other areas of research for potential applications include stimulation of stem cells and wound healing.
Founded in 2001, IR BioSciences Holdings, Inc. has moved from the academic/research phase to become a focused drug development firm centered on the compound Homspera. Having raised approximately $16 million since its founding, the company has placed contract and partnered studies in laboratories and testing facilities around the world.
ImmuneRegen has demonstrated Homspera’s biological activity in a number of preclinical animal models that in aggregate support potential clinical indications with current market values over $25 billion. With a current market capitalization of approximately $3 million, a risk mitigation strategy that includes multiple indications in both the commercial and government spheres, and the low operational overhead of a virtual company, ImmuneRegen represents an early-stage opportunity with considerable upside potential.